Skip Navigation
Menu
Original Research |1 January 2002

Risk Factors for Helicobacter pylori Resistance in the United States: The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993–1999

Joette M. Meyer, PharmD; Nancy P. Silliman, PhD; Wenjin Wang, PhD; Nancy Y. Siepman, PhD; Jennifer E. Sugg, MS; David Morris, PhD; Jie Zhang, PhD; Helen Bhattacharyya, PhD; Eileen C. King, PhD; Robert J. Hopkins, MD, MPH + TM

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Disclaimer: This article contains the professional views of the authors and does not necessarily represent the official position of the U.S. Food and Drug Administration.
Requests for Single Reprints: Joette M. Meyer, PharmD, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Pharmaceutical Evaluation III (HFD-880), 9201 Corporate Boulevard, Room S-402, Rockville, MD 20850.
Current Author Addresses: Dr. Meyer: Division of Drug Evaluation III (HFD-880), 9201 Corporate Boulevard, Room S-402, Rockville, MD 20850.
Dr. Silliman: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Biostatistics III (HFD-725), 9201 Corporate Boulevard, Rockville, MD 20850.
Dr. Wang: Wyeth-Ayerst Research, Box 8299, Philadelphia, PA 19101.
Dr. Siepman: TAP Pharmaceutical Products, Inc., 675 North Field Drive, Lake Forest, IL 60045.
Ms. Sugg: AstraZeneca L.P., 725 Chesterbrook Boulevard, D-3W, Wayne, PA 19087-5677.
Drs. Morris and Zhang: Abbott Laboratories, 100 Abbott Park Road, D-491, AP6B-1SW, Abbott Park, IL 60064-6124.
Dr. Bhattacharyya: Pfizer Central Research, 235 East 42nd Street, New York, NY 10017-5755.
Dr. King: Procter & Gamble Pharmaceuticals, Inc., Box 8006, Mason, OH 45040.
Dr. Hopkins: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Special Pathogen and Immunologic Drug Products (HFD-590), 9201 Corporate Boulevard, Rockville, MD 20850.
Author Contributions: Conception and design: J.M. Meyer, R.J. Hopkins.
Analysis and interpretation of the data: J.M. Meyer, N.P. Silliman.
Drafting of the article: J.M. Meyer, R.J. Hopkins.
Critical revision of the article for important intellectual content: J.M. Meyer, N.P. Silliman, N.Y. Siepman, J.E. Sugg, D. Morris, J. Zhang, R.J. Hopkins.
Final approval of the article: J.M. Meyer, N.P. Silliman, N.Y. Siepman, E.C. King, H. Bhattacharyya, R.J. Hopkins.
Statistical expertise: N.P. Silliman, W. Wang, N.Y. Siepman, D. Morris, J. Zhang, E.C. King.
Collection and assembly of data: J.M. Meyer, W. Wang, N.Y. Siepman, J.E. Sugg, D. Morris, J. Zhang, H. Bhattacharyya, E.C. King.
  • From U.S. Food and Drug Administration, Rockville, Maryland; Wyeth-Ayerst Research, Philadelphia, and AstraZeneca L.P., Wayne, Pennsylvania; TAP Pharmaceutical Products, Inc., Deerfield, and Abbott Laboratories, Abbott Park, Illinois; Pfizer Central Research, New York, New York; and Procter & Gamble, Mason, Ohio.
×
FULL TEXT
Disclaimer: This article contains the professional views of the authors and does not necessarily represent the official position of the U.S. Food and Drug Administration.
Requests for Single Reprints: Joette M. Meyer, PharmD, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Pharmaceutical Evaluation III (HFD-880), 9201 Corporate Boulevard, Room S-402, Rockville, MD 20850.
Current Author Addresses: Dr. Meyer: Division of Drug Evaluation III (HFD-880), 9201 Corporate Boulevard, Room S-402, Rockville, MD 20850.
Dr. Silliman: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Biostatistics III (HFD-725), 9201 Corporate Boulevard, Rockville, MD 20850.
FULL TEXT
PDF
Not Available
Citations
Citation

Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, et al. Risk Factors for Helicobacter pylori Resistance in the United States: The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993–1999. Ann Intern Med. ;136:13–24. doi: 10.7326/0003-4819-136-1-200201010-00008

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2002;136(1):13-24.

DOI: 10.7326/0003-4819-136-1-200201010-00008

147 Citations

Related Articles
The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections
Annals of Internal Medicine; 139 (6): 463-469
Collateral Damage
Annals of Internal Medicine; 139 (6): 523-524
Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–Based Triple Therapy for Helicobacter pylori Eradication
Annals of Internal Medicine; 147 (8): 553-562
Update in Gastroenterology and Hepatology
Annals of Internal Medicine; 141 (5): 374-380
View MoreView Less

Journal Club
Quadruple-drug therapy was better than triple-drug therapy for eradicating Helicobacter pylori in adults
Annals of Internal Medicine; 154 (12): JC6-2
Eradication of H. pylori after endoscopic resection for early gastric cancer reduced risk for metachronous gastric cancer
Annals of Internal Medicine; 149 (10): JC5-12
In older patients with UTIs, trimethoprim vs amoxicillin was linked to higher risk for AKI at 14 d
Annals of Internal Medicine; 168 (10): JC58
Early vs deferred endovenous ablation reduced time to ulcer healing in venous leg ulcers with varicose veins
Annals of Internal Medicine; 169 (4): JC18
View MoreView Less

Related Point of Care
Venous Leg Ulcers
Annals of Internal Medicine; 165 (3): ITC17-ITC32
View MoreView Less

Related Topics
Gastroenterology/Hepatology
H. Pylori
Infectious Disease
Peptic Disease

Gastroenterology/Hepatology, H. Pylori, Infectious Disease, Peptic Disease.

PubMed Articles
[Eradication Rates of 10-day Sequential Therapy for Helicobacter pylori: Results of an 8-year Prospective Study Conducted at a Tertiary Korean Hospital].
Korean J Gastroenterol 2019;73(2):99-104.
[Functional Dyspepsia].
Korean J Gastroenterol 2019;73(2):77-83.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×